Paul Peter Tak Candel Therapeutics, Inc. (CADL) insider trading activity

Paul Peter Tak is Chief Executive Officer of Candel Therapeutics, Inc.. Currently has a direct ownership of 225,740 shares of CADL, which is worth approximately $1.17 Million. The most recent transaction as insider was on Mar 19, 2025, when has been sold 400 shares (Common Stock) at a price of $9.0 per share, resulting in proceeds of $3,600. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 226K

10.39% 3M change

39.57% 12M change

Total Value Held $1.17 Million

Paul Peter Tak Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 19 2025	SELL Open market or private sale	$3,600 $9.0 p/Share	400 Reduced 0.18%	225,740 Common Stock
Mar 18 2025	SELL Open market or private sale	$226,020 $8.77 p/Share	25,772 Reduced 10.23%	226,140 Common Stock
Jan 15 2025	SELL Open market or private sale	$156,702 $7.22 p/Share	21,704 Reduced 7.93%	251,912 Common Stock
Jan 08 2025	SELL Open market or private sale	$174,033 $8.22 p/Share	21,172 Reduced 7.18%	273,616 Common Stock
Nov 29 2024	SELL Open market or private sale	$222,742 $4.56 p/Share	48,847 Reduced 14.21%	294,788 Common Stock
Nov 21 2024	BUY Exercise of conversion of derivative security	$19,995 $1.55 p/Share	12,900 Added 3.62%	343,635 Common Stock
Jul 17 2024	SELL Open market or private sale	$145,756 $6.47 p/Share	22,528 Reduced 6.38%	330,735 Common Stock
Jul 11 2024	SELL Open market or private sale	$121,149 $5.97 p/Share	20,293 Reduced 5.43%	353,263 Common Stock
Nov 28 2023	SELL Payment of exercise price or tax liability	$39,098 $0.9 p/Share	43,443 Reduced 10.42%	373,556 Common Stock
Nov 26 2023	BUY Grant, award, or other acquisition	-	180,108 Added 30.16%	416,999 Common Stock
Dec 09 2022	BUY Open market or private purchase	$24,835 $1.92 p/Share	12,935 Added 23.99%	40,985 Common Stock
Dec 08 2022	BUY Open market or private purchase	$5,185 $1.7 p/Share	3,050 Added 9.81%	28,050 Common Stock
Nov 28 2022	BUY Grant, award, or other acquisition	-	195,906 Added 47.0%	220,906 Common Stock
Jul 29 2021	BUY Open market or private purchase	$200,000 $8.0 p/Share	25,000 Added 50.0%	25,000 Common Stock

PPT

Paul Peter Tak

Chief Executive Officer

Needham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CADL shares.

Notify only if

Value

Insider Trading

Get notified when an Candel Therapeutics, Inc. insider buys or sells CADL shares.

Notify only if

Operation

Value

Type

News

Receive news related to Candel Therapeutics, Inc.

Track Activities on CADL

Account